This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) raised its 2026 outlook again Wednesday after stronger-than-expected third-quarter results, with the newly launched Wegovy pill emerging as the clearest bright spot in the company's effort to regain momentum in obesity drugs. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The Danish drugmaker now expects adjusted sales and operating profit growth of between 2% and negative 2% at constant exchange rates, improved from its previous range of flat to a 6% decline. It marks the third guidance raise this year. The Wegovy pill drove much of the optimism. Launched in the U.S.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.